# A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

> **NCT06889701** · PHASE1,PHASE2 · RECRUITING · sponsor: **TenNor Therapeutics Inc.** · enrollment: 33 (estimated)

## Conditions studied

- Periprosthetic Joint Infection (PJI)

## Interventions

- **DRUG:** TNP-2092 for injection
- **DRUG:** Vancomycin Hydrochloride for Injection (IA)
- **DRUG:** Vancomycin Hydrochloride for Injection (IV)
- **DRUG:** Oral antibiotics
- **DRUG:** Background Treatment

## Key facts

- **NCT ID:** NCT06889701
- **Lead sponsor:** TenNor Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889701, "A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06889701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*